Our study indicated that combined usage of BLU-554 and KX2-391 significantly inhibited ELF4-mediated CRC metastasis in vitro and in vivo compared with vehicle or monotherapy treatment, highlighting the potential for BLU-554 and KX2-391 combination therapy in the treatment of mCRC. Here, ELF4 is linked to colorectal carcinoma.